Brief: Alphamab Oncology Says Simcere Pharmaceutical Granted An Exclusive Marketing Right In PRC
30/03/2020 10:46
March 30 (Reuters) - Alphamab Oncology 9966.HK :
* SIMCERE PHARMACEUTICAL GRANTED AN EXCLUSIVE MARKETING
RIGHT IN
RESPECT OF ONCOLOGY INDICATIONS OF KN035 IN PRC
Source text for Eikon: urn:newsml:reuters.com:*:nHKS13SHJM
Further company coverage: 9966.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alphamab Oncology
See all newsBrief: Alphamab Oncology Says Fei Wang Resigns As Chief Financial Officer
Brief: Alphamab Oncology Says First Patient Dosed In Phase III Clinical Study Of JSKN033 Monotherapy For Treatment Of Cervical Cancer
Brief: Alphamab Oncology Says Board Resolves To Repurchase Shares Up To HK$80 Million In Value
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab With HB1801 For Her2+ Advanced Breast Cancer
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab (KN026)